Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News on Pharma

Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now

Hims Hers Health Inc. (NYSE:HIMS) has been one of 2025’s hottest telehealth stocks, nearly doubling in value year to date, but a deepening clash with Novo Nordisk A/S (NYSE:NVO) over compounded weight-loss drugs, and shifting FDA rules, has turned momentum into headwinds, sending shares sliding 10% in the past three…

Benzinga

Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst

Shares of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) are trading sharply higher Tuesday morning following the release of the company’s second-quarter financial results and operational update.

Benzinga

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts

Avantor Inc. (NYSE:AVTR) stock rose after Engine Capital LP, which holds roughly 3% of the company, urged management in a letter to consider a sale, refresh its board, boost share repurchases, cut costs, and divest non-core assets.

Benzinga

Why Quantum BioPharma (QNTM) Stock Is Soaring Today

Shares of Quantum BioPharma Ltd (NASDAQ:QNTM) are on watch Monday morning following a series of updates regarding its lead drug candidate for multiple sclerosis, Lucid-MS. Here’s what investors need to know.

Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction

In a stunning reversal, Dr. Vinay Prasad is returning to his role as director of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), just days after his resignation.

Benzinga

Attorney says heart device did not shock Tennessee man in execution who said he was 'hurting so bad'

The attorney for a Tennessee man who said he was “hurting so bad” during his lethal injection this week says his implanted defibrillator did not shock him

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Gilead Sciences Lifts Annual Outlook As Yeztugo Launch Nears

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

Benzinga

Becton Dickinson Q3 Beats Estimates On Medical Device Boom

As the healthcare industry continues to rebound from global disruptions, companies like Becton, Dickinson, and Company (NYSE:BDX) are reporting robust financial performances that highlight their resilience and strategic adaptability. The company’s stock is trading higher on Thursday on better-than-expected third-quarter 2025 earnings.

Benzinga

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

The Independent UK

Amgen Stock Sinks As Market Eyes MariTide's Next Move

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Benzinga

Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the consensus of $80.354 billion.

Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Benzinga

Shares in European drug companies hit four-month low as Trump tariffs loom

President repeats threat to bring in levies ‘within next week or so’ in attempt to get companies to move production to US

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Ozempic Maker Novo Nordisk Terminates Multiple Pipeline Programs, Faces Investor Lawsuit Over GLP-1 Market Misrepresentation

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish kroner), missing the consensus of $11.79 billion.

Evening Standard

Fake Viagra is the UK’s most seized counterfeit drug - here's how to avoid it

Fake Viagra, real problems – the UK’s most seized counterfeit drug revealed

Benzinga

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Kiplinger

Ozempic, Botox, Eliquis: How Tariffs on Europe Could Impact Drug Prices (And What To Do About It)

Most medications come from Europe. Does that mean the new tariffs on the EU will drive drug prices higher?

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:BMRN) reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.

Benzinga

Pfizer Cost-Cut Initiatives More Than Offset Tariffs Impact, Raises Outlook

On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter 2025 adjusted earnings of 78 cents, compared to 60 cents a year ago, beating the consensus of 57 cents.

Benzinga

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

Benzinga

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Benzinga

Twist Bioscience Turns The Tide: Q3 Sales Jump, Beats Earnings

What if a biotech company could flip its financial narrative from loss to profit in just a year? Twist Bioscience Corporation (NASDAQ:TWST) has done just that, reporting a surprising third-quarter income that defied analysts’ expectations

Benzinga

Praxis' Epilepsy Treatment Shows Promise With Decreased Seizures

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) stock experienced a volatile trading session on Monday, after the company announced positive topline results from its Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures and generalized epilepsy.

Benzinga

Briumvi's Strong Sales Can't Stop TG Therapeutics Stock Slide

TG Therapeutics Inc. (NASDAQ:TGTX) stock is trading lower on Monday after the company reported worse-than-expected second-quarter 2025 earnings.

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Health and Human Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.